Factors Associated with Willingness to Participate in HIV Vaccine Trials among High-Risk Populations in South India
- 1 February 2009
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 25 (2) , 217-224
Abstract
Successful conduct of any HIV vaccine trial (HIVVT) requires a high level of preparedness in the community. A cross-sectional study was conducted in Tamilnadu, India among 501 participants from six different risk groups to investigate their willingness to participate (WTP) in future preventive HIVVTs and to explore their knowledge and attitude toward preventive HIV vaccines. In total, 82% were willing to participate and the desire to be protected from HIV was the main reason for WTP. Perception of not being at risk was the major reason for refusal among married women. The knowledge scale showed a significant increase in scores after vaccine education. In all, 76% revealed the hope that there would be an effective vaccine in a few years and 71% hoped that the HIV vaccine would protect them from HIV infection. The main concern was the unknown efficacy of the vaccine (50%) and the effects of an HIV vaccine on participants' lives (51%). Overall, 76% agreed that sex without a condom would not be safe whether or not there was an HIV vaccine. To conclude, it is likely that high-risk volunteers will be willing to enroll in preventive HIVVTs. Addressing barriers and concerns by providing information through appropriate agencies will spell out success for preventive HIVVTs in India.Keywords
This publication has 19 references indexed in Scilit:
- Willingness to participate in HIV vaccine trials: The impact of trial attributesPreventive Medicine, 2007
- HIV in India — A Complex EpidemicNew England Journal of Medicine, 2007
- Perceptions of a Community Sample about Participation in Future HIV Vaccine Trials in South IndiaAIDS and Behavior, 2006
- Correlates of HIV vaccine trial participation: an Indian perspectiveVaccine, 2005
- Challenges for HIV Vaccine Dissemination and Clinical Trial Recruitment: If We Build It, Will They Come?AIDS Patient Care and STDs, 2004
- What Constitutes Efficacy for a Human Immunodeficiency Virus Vaccine that Ameliorates Viremia: Issues Involving Surrogate End Points in Phase 3 TrialsThe Journal of Infectious Diseases, 2003
- Willingness to Participate in HIV-1 Vaccine Efficacy Trials and the Effect of Media Events Among Gay and Bisexual Men in New York CityJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Willingness to participate in AIDS vaccine trials among high-risk populations in northern ThailandAIDS, 1995
- Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San FranciscoScience, 1994
- The MOS social support surveySocial Science & Medicine, 1991